STOCKHOLM, Sweden, July 14, 2005 (PRIMEZONE) -- Vitrolife:
- Sales increased by 10 percent to SEK 60.8 (55.1) million. Adjusted for exchange-rate effects the increase was 12 percent. During the second quarter sales amounted to SEK 30.3 (25.6) million, corresponding to an increase of 18 percent. Adjusted for exchange-rate effects the increase was 20 percent.
- Gross income increased by 6 percent to SEK 41.8 (39.3) million and the gross margin amounted to 69 (71) percent. Gross income for the second quarter increased by 13 percent to SEK 21.3 (18.8) million and the gross margin was 70 (73) percent.
- Operating income amounted to SEK 6.5 (8.6) million for the first six months and to SEK 1.1 (3.2) million for the second quarter.
- Net income for the Group was SEK 9.0 (9.2) million, of which SEK 2.8 million (3.0) was for the second quarter.
- Earnings per share amounted to SEK 0.49 (0.50).
- The equity/assets ratio increased to 82 percent (80).
- The validation of the GIII Series products at the Denver facility has been completed.
- All parts of the new office building and warehouse in Kungsbacka are now in use.
July 14, 2005 Kungsbacka, Sweden
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has over 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
Vitrolife AB (publ), Faktorvagen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=115653&fn=wkr0001.pdf